-
Mashup Score: 1British Journal of Haematology: Vol 206, No 1 - 5 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1British Journal of Haematology: Vol 206, No 1 - 5 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
RT @DrAEvens: 🚨🚨🚨 The January 2025 edition of @BrJHaem is online. SEE HERE: https://t.co/YfZLlX33ei A multitude of outstanding contributi…
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 75
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/HfLB7dCyER
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 26
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/Acus5vGJcN
-
-
Mashup Score: 75
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/HfLB7dCyER
-
RT @DrAEvens: 🚨🚨🚨 The January 2025 edition of @BrJHaem is online. SEE HERE: https://t.co/YfZLlX33ei A multitude of outstanding contributi…